Skip to main content
Shattuck Labs, Inc. logo

Shattuck Labs, Inc. — Investor Relations & Filings

Ticker · STTK ISIN · US82024L1035 US Manufacturing
Filings indexed 361 across all filing types
Latest filing 2026-01-13 Director's Dealing
Country US United States of America
Listing US STTK

About Shattuck Labs, Inc.

https://www.shattucklabs.com/

Shattuck Labs, Inc. is a biotechnology company that develops biologic medicines for inflammatory and immune-mediated diseases. The company specializes in Tumor Necrosis Factor (TNF) receptor modulators, utilizing its expertise in protein engineering to create novel therapeutics. Its lead program, SL-325, is a potentially first-in-class monoclonal antibody designed as an antagonist of Death Receptor 3 (DR3). This program targets the clinically validated TL1A/DR3 pathway to achieve a deep and durable blockade for the treatment of conditions such as Inflammatory Bowel Disease (IBD) and other inflammatory autoimmune diseases.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2026-01-13 English
4
Director's Dealing
2026-01-13 English
4
Director's Dealing
2026-01-13 English
S-3
Regulatory Filings
2026-01-13 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English
8-K/A
Regulatory Filings
2025-11-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.